Study details
Enrolling now
Empagliflozin Trial to Reduce Arterial Stiffness in Older Adults
University of Missouri-Columbia
NCT IDNCT06506422ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2/3
Target enrollment
80
Study length
about 4.5 years
Ages
60–80
Locations
1 site in MO
What this study is about
Researchers are testing whether empagliflozin, a medication, can help reduce arterial stiffness in older adults. The trial involves randomly assigning participants aged 60-80 to either empagliflozin or a placebo for 12 weeks. It will last approximately 1655 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Empagliflozin 10 MG
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
empagliflozin (SGLT2 inhibitor; increases glucose excretion in urine)
Endpoints
Primary: Carotid Femoral Pulse Wave Velocity (cfPWV)